2.A Case of Aplastic Anemia Following Hepatitis.
Chul Ho LEE ; Hyo Jyung KIM ; Hye Kyung LEE ; Soon Jae LEE
Journal of the Korean Pediatric Society 1983;26(1):81-85
No abstract available.
Anemia, Aplastic*
;
Hepatitis*
3.Functional Dyspepsia and Subgroups in Korea and Short Term Outcome of Therapeutic Trial of Cisapride: Multicenter Study.
Chung HUH ; Chang Heon YANG ; Jae Guen JANG ; Dong Ho LEE ; Kook Lae LEE ; Sang Young SEOL ; Youn Jae LEE ; Sok Won HAN ; Kyu Sung RIM ; Poong Lyul RHEE ; Won Chang SHIN ; Kwang Jae LEE ; Moon Kwan CHUNG ; Yong Ho NAH ; Jun Myeong KIM ; Do Young KIM ; Sun Young LEE ; Pum Soo KIM ; Don Haeng LEE ; Yong Woon SHIN ; Kye Sook KWON ; Jong Sun REW ; Hyun Chul PARK ; Hwoon Yong JUNG ; Young Il MIN ; Sang In LEE ; Myung Gyu CHOI ; Kyu Wan CHOI ; Na Young KIM ; Seon Hee LIM ; Kye Heui LEE ; Sung Kook KIM ; Yong Hwan CHOI ; Chi Wook SONG ; Heu Rang KIM ; Chang Young YIM ; Jyung Dong BAE ; Pil Joong KANG ; Byung Min AHN ; Soo Heon PARK ; Hyun Yong JEONG ; Sei Jin YOUN ; Hyang Soon YEO ; Jeong Seop MOON ; Hyo Jin PARK ; Hak Yang KIM ; Sang Woo LEE ; Yong Chan LEE ; Moon Ho LEE ; Seong Ho CHOI ; Mi Hye JUNG ; Chan Sup SHIM ; Joon Seong LEE ; Young Woo KANG ; Jong Chul RHEE
Korean Journal of Gastrointestinal Motility 1998;4(1):1-12
BACKGROUND/AIMS: The aims of this study were to determine subgoups of functional dyspesia and to evaluate the short-term effect of cisapride in patients with functional dyspepsia in Korea. METHODS: 1025 patients, with a mean age of 42.6 years, with symptoms of functional dyspepsia, were recruited consecutively and upper gastrointestinal symptoms were investigated by interview in 41 hospitals in Korea. In an open, multicenter trial, 1025 patients received Smg of cisapride three times a day (TID) for at least .2 weeks for the treatment of symptoms of functional dyspepsia. When necessary, the dose of cisapride was increased to 10mg TID and the duration of therapy was extended to 4 weeks. RESULTS: The most frequently reported symptoms of functional dyspepsia were epigastric discomfort or fullness (85%), bloating (70%), belching (53%), early satiety (52%) and epigastric pain (46%) retrospectively. Subgroups of functional dyspepsia were as follows; dysmotility-like 73.5%, ulcer-like 39.7%, reflux-like 13.0%, and unspecified dyspepsia 14.0%. However, 33.2% of subjects with functional dyspepsia could be classified into more than one subgroup. Upper gastrointestinal symptoms were decreased to average 50.3% (range; 42.2 to 59.2%) after 2 weeks of cisapride treatment and to 25% (19.2 to 29.9%) after 4 weeks. cisapride therapy resulted in good or excellent improvement in 59.0% of the patients after two weeks, in 75% of patients after 4 weeks. Adverse events were occurred in 52 patients (5.8% of all patients), most commonly, loose stools or diarrhea (3.5%), abdominal pain (1.1%), and dizziness (0.3%). The majority of adverse events was mild and transient in nature and led to premature discontinuation of treatment in 4 patients. CONCLUSIONS: Although the majorities of patients with functional dyspepsia have dysmotility like symptoms in Korea, there is such overlap among the dyspepsia subgroups. Most patients responded well to a short therapeutic trial with cisapride without significant side effects.
Abdominal Pain
;
Cisapride*
;
Diarrhea
;
Dizziness
;
Dyspepsia*
;
Eructation
;
Humans
;
Korea*
;
Retrospective Studies
Result Analysis
Print
Save
E-mail